$CRDFSep 2, 2026, 11:00 AMAI processed
Cardiff Oncology (CRDF) to Present at Sept 2026 RAS Summit and H.C. Wainwright Conference
AI Summary
Cardiff Oncology (NASDAQ: CRDF) said Mani Mohindru, Ph.D. will present on Sept. 8 at the 8th Annual RAS-Targeted Drug Development Summit and participate in a fireside chat at the H.C. Wainwright Global Investment Conference on Sept. 14; slides and a webcast replay will be available on the company website. Management will use these events to discuss onvansertib, the company’s oral PLK1 inhibitor currently in a Phase 2 trial for first-line RAS‑mutated metastatic colorectal cancer, which could increase investor visibility ahead of any clinical updates.
Positives
- Management slated to present at a targeted scientific RAS summit and a major investor conference (Sept. 8 and Sept. 14).
- Slides and a live/replay webcast will be made available, improving investor access to the presentation.
- Highlights company’s lead asset onvansertib, currently in Phase 2 for first-line RAS‑mutated mCRC.
Negatives
- No new clinical data or trial readout was announced in the release.
- Presentation content may be promotional and is not guaranteed to include material efficacy or safety results.
- Onvansertib program remains early-stage (Phase 2), so clinical and commercial risk persists.